Chronic Spontaneous Urticaria (CSU) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
-1.jpg)
Chronic spontaneous urticaria (CSU)
also called chronic idiopathic urticarial is characterized by the occurrence of
urticaria for 6 weeks or longer without identifiable specific triggers. The
average duration of CSU is frequently reported as 5 years, but maybe longer in
more severe cases specifically, in patients with concurrent angioedema.
Patients with chronic urticaria (used as a proxy for CSU) experience the
substantial health-related quality of life (HRQoL) and productivity impairments
and increased psychological comorbidities relative to patients without chronic
urticarial. CSU is the spontaneous development of signs and symptoms with no
known specific trigger. CSU and CIndU may coexist in the same patient. Overall
urticaria is classified as acute or chronic form based on the duration of
illness. Chronic urticaria is diagnosed when the disease has been continuously
or intermittently present for at least 6 weeks. The chronic and acute forms of
urticaria differ in etiology, pathophysiology, and the underlying mechanism.
- The prevalence of chronic spontaneous urticaria (CSU) was
estimated to be 0.75% to 1.02% cases within adults, however, ~ 30% to 55%
of patients are diagnosed and symptomatic. 10% to 15% of patients are
being diagnosed with mild, 29% to 31% of patients are being diagnosed with
moderate and 27% to 29% patients are being diagnosed with a severe type of
CSU.
Thelansis’s “Chronic Spontaneous
Urticaria (CSU) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Chronic
Spontaneous Urticaria (CSU) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Chronic Spontaneous Urticaria (CSU) across 8 MM market from the centre of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Chronic Spontaneous Urticaria (CSU) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment